| __timestamp | Arrowhead Pharmaceuticals, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 23138050 | 100244000 |
| Thursday, January 1, 2015 | 57410147 | 29674000 |
| Friday, January 1, 2016 | 41454452 | 14917000 |
| Sunday, January 1, 2017 | 31690298 | 14118000 |
| Monday, January 1, 2018 | 52968505 | 8737000 |
| Tuesday, January 1, 2019 | 81048686 | 6900000 |
| Wednesday, January 1, 2020 | 128874979 | 6248000 |
| Friday, January 1, 2021 | 206342000 | 12312000 |
| Saturday, January 1, 2022 | 297307000 | 19721000 |
| Sunday, January 1, 2023 | 353188000 | 31283000 |
| Monday, January 1, 2024 | 505870000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Arrowhead Pharmaceuticals, Inc. and MannKind Corporation have taken distinct paths in their research and development (R&D) spending over the past decade. Since 2014, Arrowhead has consistently increased its R&D investment, with a staggering 2,100% growth by 2023. This commitment to innovation is evident as their R&D expenses soared from just over $23 million in 2014 to more than $500 million in 2024. In contrast, MannKind's R&D spending has been more conservative, peaking at around $31 million in 2023, a modest 69% increase from 2014. This divergence highlights Arrowhead's aggressive pursuit of innovation, while MannKind adopts a more cautious approach. As the pharmaceutical landscape continues to shift, these strategies will undoubtedly shape their future trajectories.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viatris Inc. vs Arrowhead Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Spending Showdown: Opthea Limited vs Arrowhead Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs MannKind Corporation
R&D Insights: How PTC Therapeutics, Inc. and MannKind Corporation Allocate Funds
Research and Development Expenses Breakdown: Veracyte, Inc. vs MannKind Corporation
Analyzing R&D Budgets: Veracyte, Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Arrowhead Pharmaceuticals, Inc. and Novavax, Inc.